Abstract
Transgender is defined as an incongruence between the assigned at birth sex and an experienced gender identity. The biological sex is neither familiar nor acceptable to transgender people. Gender-affirming hormone treatment (GHT) is a multidisciplinary approach aiming to develop and maintain physical characteristics of the desirable sex. The influence of exogenous hormones on the cancer pathogenesis and development is a subject of ceaseless studies and observations. However incomplete statistical and epidemiological data hamper deducing about the risk of cancer among these people. The article describes a case of a transgender female-to-male (FtM) patient during gender transition with two primary neoplasms (endometrial cancer and colon cancer) as well as Lynch syndrome and von Recklinghausen’s disease confirmed by next-generation sequencing (NGS).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
